Generated by AI
GRI Bio Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory, fibrotic, and autoimmune diseases. GRI Bio’s current pipeline centers on Natural Killer T cell modulators designed to help regulate immune responses that contribute to serious disease progression. Its lead program, GRI-0621, is an oral candidate being developed for severe fibrotic lung diseases, including idiopathic pulmonary fibrosis. The company is also advancing GRI-0803 for autoimmune disorders, alongside additional early-stage programs and a proprietary library of compounds that support its research pipeline. Based in La Jolla, California, GRI Bio Inc. operates in the biotechnology sector and concentrates on translating immune-system biology into drug candidates for unmet medical needs in specialty disease areas.
Website2223 Avenida de la Playa
La Jolla, CA, 92037
United States
The latest articles about GRI.
GRI Bio, Inc. (GRI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
New whole blood RNA sequencing data identified coordinated, consistent change in genes governing immune re-balancing, myofibroblast inhibition, fibrolysis, basement membrane repair, re-epithelialization, antitussive effect and GI protection Signals observed from at least two independent measurement modalities, including RNA sequencing, serum extracellular matrix biomarkers, spectral flow cytometry and clinical readouts, supported each of the nine pre-specified mechanistic pillars, defining a rep
Summary of Sep 8's posts. Generated by AI.
Summary of Aug 11's posts. Generated by AI.
Summary of Sep 4's posts. Generated by AI.
Investors talking about GRI also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.